Related Experiment Video

Updated: Jul 7, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Impact of therapeutic advances on hypoglycaemia in type 2 diabetes

Patrick J Boyle1, John Zrebiec

  • 1Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131, USA. pboyle@salud.unm.edu

Diabetes/Metabolism Research and Reviews
|January 31, 2008
PubMed

Insights

New diabetes therapies reduce hypoglycemia risk for type 2 diabetes patients. Advancements in pharmacotherapy, drug delivery, and glucose monitoring improve glycemic control while minimizing hypoglycemia, but patient education is key.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacotherapy and Drug Delivery Systems
  • Diabetes Management and Technology

Background:

  • Type 2 diabetes patients experience less frequent hypoglycemia than type 1 diabetes patients due to intact glucose counter-regulatory pathways.
  • Intensive glycemic control in type 2 diabetes can increase hypoglycemia risk, potentially leading to clinical inertia among healthcare providers.
  • Maintaining optimal glycemic control is crucial for public and individual health, driving the development of new therapeutic strategies.

Purpose of the Study:

  • To review and evaluate recent advancements in diabetes therapies and technologies.
  • To determine if these advancements facilitate achievement of glycemic goals while minimizing hypoglycemia incidence.
  • To assess the impact of pharmacotherapy, drug delivery systems, and blood glucose monitoring on hypoglycemia in type 2 diabetes.

Main Methods:

  • Review of recent literature on pharmacotherapy for type 2 diabetes.
  • Analysis of advancements in drug delivery systems and blood glucose (BG) monitoring technologies.
  • Clinical perspective assessment of the impact of these advancements on hypoglycemia incidence and severity.

Main Results:

  • Recent progress in pharmacotherapy, drug delivery systems, and BG monitoring has a largely positive impact on reducing hypoglycemia incidence in type 2 diabetes.
  • These advancements offer the potential to achieve glycemic goals more effectively with a lower risk of hypoglycemia compared to traditional therapies.
  • The successful implementation of these advancements is contingent upon patient and provider education, motivation, and behavioral changes.

Conclusions:

  • Modern therapeutic advancements positively influence hypoglycemia management in type 2 diabetes.
  • Improved glycemic control with minimized hypoglycemia is achievable through new therapies and technologies.
  • Patient and provider engagement is critical for realizing the full benefits of these advancements over traditional treatments.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...